TrialThe Lancet. Microbe2023

Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.

Nancy H L Leung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.